Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases
Aim. To determine the potential role of conventional and potential biomarkers in predicting major adverse cardiovascular events (MACE) in the long-term period after coronavirus disease 2019 (COVID-19).Material and methods. On the day of hospitalization, 112 inpatients with a confirmed diagnosis of C...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2025-05-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/4345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850027301726584832 |
|---|---|
| author | T. V. Kanaeva N. A. Karoli |
| author_facet | T. V. Kanaeva N. A. Karoli |
| author_sort | T. V. Kanaeva |
| collection | DOAJ |
| description | Aim. To determine the potential role of conventional and potential biomarkers in predicting major adverse cardiovascular events (MACE) in the long-term period after coronavirus disease 2019 (COVID-19).Material and methods. On the day of hospitalization, 112 inpatients with a confirmed diagnosis of COVID-19 were assessed for biomarkers such as high-sensitivity troponin T (hsTnT) and troponin I (hsTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), D-dimer, soluble tumorigenicity suppression protein (sST2) and pentraxin 3 (PTX3). COVID-19 survivors were followed for a median period of 366 [365; 380] days after discharge from the COVID hospital, assessing the incidence of MACE (myocardial infarction, pulmonary embolism, cerebrovascular accident, cardiovascular death).Results. During the one-year follow-up period, the study endpoints (MACE) were registered in 14 (12,5%) patients. Of the cardiovascular biomarkers studied, differences were found in the levels of both conventional (hsTnT, D-dimer) and potential biomarkers (sST2, PT3) in the groups of patients with and without MACE. Groups did not differ significantly in NT-proBNP and hsTnI levels (p>0,05). According to multivariate analysis, the strongest predictors of MACE development are body mass index >29,5 kg/m2 (Area Under The ROC Curve (AUC) 0,672, sensitivity 45%, specificity 23,9%, p=0,001), PTX3 >3,1 ng/ml (AUC 0,885, sensitivity 94,0%, specificity 82,1%, p=0,001), sST2 >36 ng/ml (sensitivity 92,9%, specificity 33%, p=0,001), D-dimer >0,4 μg/ml (AUC 0,787, sensitivity 93%, specificity 72,4%, p=0,049). A mathematical model based on the concentration of PTX3, sST2 and D-dimer biomarkers predicts MACE within 1 year after COVID-19 with a sensitivity of 92,9%, specificity of 61% and predictive accuracy of 90,5% (p<0,001).Conclusion. Determination of the concentration of biomarkers such as D-dimer, sST2, PT3 can be used to predict long-term MACE in patients after COVID-19. |
| format | Article |
| id | doaj-art-e0dbece6c86c4dabbd000786a2d81fb6 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2025-05-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-e0dbece6c86c4dabbd000786a2d81fb62025-08-20T03:00:14Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252025-05-0124410.15829/1728-8800-2025-43453233Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseasesT. V. Kanaeva0N. A. Karoli1Razumovsky Saratov State Medical UniversityRazumovsky Saratov State Medical UniversityAim. To determine the potential role of conventional and potential biomarkers in predicting major adverse cardiovascular events (MACE) in the long-term period after coronavirus disease 2019 (COVID-19).Material and methods. On the day of hospitalization, 112 inpatients with a confirmed diagnosis of COVID-19 were assessed for biomarkers such as high-sensitivity troponin T (hsTnT) and troponin I (hsTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), D-dimer, soluble tumorigenicity suppression protein (sST2) and pentraxin 3 (PTX3). COVID-19 survivors were followed for a median period of 366 [365; 380] days after discharge from the COVID hospital, assessing the incidence of MACE (myocardial infarction, pulmonary embolism, cerebrovascular accident, cardiovascular death).Results. During the one-year follow-up period, the study endpoints (MACE) were registered in 14 (12,5%) patients. Of the cardiovascular biomarkers studied, differences were found in the levels of both conventional (hsTnT, D-dimer) and potential biomarkers (sST2, PT3) in the groups of patients with and without MACE. Groups did not differ significantly in NT-proBNP and hsTnI levels (p>0,05). According to multivariate analysis, the strongest predictors of MACE development are body mass index >29,5 kg/m2 (Area Under The ROC Curve (AUC) 0,672, sensitivity 45%, specificity 23,9%, p=0,001), PTX3 >3,1 ng/ml (AUC 0,885, sensitivity 94,0%, specificity 82,1%, p=0,001), sST2 >36 ng/ml (sensitivity 92,9%, specificity 33%, p=0,001), D-dimer >0,4 μg/ml (AUC 0,787, sensitivity 93%, specificity 72,4%, p=0,049). A mathematical model based on the concentration of PTX3, sST2 and D-dimer biomarkers predicts MACE within 1 year after COVID-19 with a sensitivity of 92,9%, specificity of 61% and predictive accuracy of 90,5% (p<0,001).Conclusion. Determination of the concentration of biomarkers such as D-dimer, sST2, PT3 can be used to predict long-term MACE in patients after COVID-19.https://cardiovascular.elpub.ru/jour/article/view/4345cardiovascular biomarkerssst2pentraxin 3d-dimeradverse cardiovascular eventscovid-19 |
| spellingShingle | T. V. Kanaeva N. A. Karoli Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases Кардиоваскулярная терапия и профилактика cardiovascular biomarkers sst2 pentraxin 3 d-dimer adverse cardiovascular events covid-19 |
| title | Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases |
| title_full | Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases |
| title_fullStr | Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases |
| title_full_unstemmed | Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases |
| title_short | Conventional (D-dimer) and potential (pentraxin 3 and sST2) biomarkers in long-term prognosis of adverse cardiovascular events in COVID-19 survivors without significant cardiovascular diseases |
| title_sort | conventional d dimer and potential pentraxin 3 and sst2 biomarkers in long term prognosis of adverse cardiovascular events in covid 19 survivors without significant cardiovascular diseases |
| topic | cardiovascular biomarkers sst2 pentraxin 3 d-dimer adverse cardiovascular events covid-19 |
| url | https://cardiovascular.elpub.ru/jour/article/view/4345 |
| work_keys_str_mv | AT tvkanaeva conventionalddimerandpotentialpentraxin3andsst2biomarkersinlongtermprognosisofadversecardiovasculareventsincovid19survivorswithoutsignificantcardiovasculardiseases AT nakaroli conventionalddimerandpotentialpentraxin3andsst2biomarkersinlongtermprognosisofadversecardiovasculareventsincovid19survivorswithoutsignificantcardiovasculardiseases |